Size: | Price | Quantity | |
---|---|---|---|
10 mg | $55.00 | ||
50 mg | $195.00 |
PK150 (2165324-62-7) is a Sorafenib analog that displays significant antibacterial activity against several pathogenic strains (S.aureus NCTC8325, MIC = 0.3 µM; vancomycin -resistant enterococci, MIC = 3 µM; and M.tuberculosis MIC = 2 µM). It was inactive against Gram-negative bacteria. It effectively reduced persister cells in ciprofloxacin-treated stationary S.aureus cultures and effectively eradicated staphylococcus biofilms. PK150 did not develop antibacterial resistance in an agar-plate-based assay. Its antibacterial properties were attributed to demethylmenaquinone methyltransferase (MenG) inhibition and signal peptidase IB (SpsB) activation. PK150 displayed in vivo efficacy in a murine bloodstream infection model against methicillin-sensitive S. aureus and a neutropenic mouse thigh model against methicillin-resistant S. aureus strain ATCC33591. Inactive against a panel of over 250 human kinases.
References/Citations:
1) Le et al. (2019) Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms; Nat. Chem. 12 145
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
PK150 (2165324-62-7) is a Sorafenib analog that displays significant antibacterial activity against several pathogenic strains (S.aureus NCTC8325, MIC = 0.3 µM; vancomycin -resistant enterococci, MIC = 3 µM; and M.tuberculosis MIC = 2 µM). It was inactive against Gram-negative bacteria. It effectively reduced persister cells in ciprofloxacin-treated stationary S.aureus cultures and effectively eradicated staphylococcus biofilms. PK150 did not develop antibacterial resistance in an agar-plate-based assay. Its antibacterial properties were attributed to demethylmenaquinone methyltransferase (MenG) inhibition and signal peptidase IB (SpsB) activation. PK150 displayed in vivo efficacy in a murine bloodstream infection model against methicillin-sensitive S. aureus and a neutropenic mouse thigh model against methicillin-resistant S. aureus strain ATCC33591. Inactive against a panel of over 250 human kinases.
References/Citations:
1) Le et al. (2019) Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms; Nat. Chem. 12 145
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.